{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Poorly+Differentiated+and+Undifferentiated+Thyroid+Cancer",
    "query": {
      "condition": "Poorly Differentiated and Undifferentiated Thyroid Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:10:32.025Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03896958",
      "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer, All Types",
        "Cancer of Liver",
        "Cancer of Stomach",
        "Cancer of Head and Neck",
        "Cancer of Rectum",
        "Cancer of Kidney",
        "Cancer of Esophagus",
        "Cancer of Colon",
        "Cancer Skin",
        "Cancer of Cervix",
        "Cancer, Metastatic",
        "Cancer of Larynx",
        "Cancer of Neck",
        "Cancer of Lung",
        "Cancer of Brain and Nervous System",
        "Cancer of Vulva, Disseminated",
        "Cancer of Pancreas",
        "Sarcoma",
        "GIST",
        "Small-cell Lung Cancer",
        "Adenocarcinoma Lung",
        "Cancer of Prostate",
        "Cancer, Advanced",
        "Adrenal Cancer",
        "Testicular Cancer",
        "Uterine Cancer",
        "Bronchoalveolar Cell Lung Cancer",
        "Cancer Unknown Primary",
        "Glioblastoma Multiforme",
        "Oligodendroglioma",
        "Breast Cancer",
        "Renal Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Cholangiocarcinoma",
        "Squamous Cell Carcinoma",
        "Transitional Cell Carcinoma",
        "Cancer, Other",
        "Cancer, Anal",
        "Melanoma",
        "Cancer, Bile Duct",
        "Cancer, Bladder",
        "Cancer Cords Vocal",
        "Cancers Cell Neuroendocrine",
        "Cancer Differentiated Poorly",
        "Cancer, Anaplastic Thyroid"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "SpeciCare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Month to 99 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2019-03-21",
      "completion_date": "2024-03-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-05-22T03:10:32.025Z",
      "location_count": 1,
      "location_summary": "Gainesville, Georgia",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03896958"
    },
    {
      "nct_id": "NCT00654238",
      "title": "Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Differentiated Thyroid Cancer",
        "Metastatic Poorly Differentiated Thyroid Cancer",
        "Metastatic Anaplastic Thyroid Cancer",
        "Metastatic Medullary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2006-02",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-05-22T03:10:32.025Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00654238"
    },
    {
      "nct_id": "NCT04171622",
      "title": "Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Thyroid Gland Squamous Cell Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-11-04",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-22T03:10:32.025Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04171622"
    },
    {
      "nct_id": "NCT03181100",
      "title": "Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Thyroid Gland Anaplastic Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2017-07-27",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-05-22T03:10:32.025Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03181100"
    },
    {
      "nct_id": "NCT04759911",
      "title": "Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Thyroid Gland Neoplasm",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Thyroid Gland Anaplastic Carcinoma",
        "Thyroid Gland Medullary Carcinoma",
        "Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-02-26",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-22T03:10:32.025Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04759911"
    },
    {
      "nct_id": "NCT03449108",
      "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bone Sarcoma",
        "Dedifferentiated Chondrosarcoma",
        "Giant Cell Tumor of Bone",
        "Malignancy in Giant Cell Tumor of Bone",
        "Malignant Solid Neoplasm",
        "Ovarian Carcinosarcoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Osteosarcoma",
        "Recurrent Ovarian Carcinoma",
        "Refractory Osteosarcoma",
        "Soft Tissue Sarcoma",
        "Thyroid Gland Anaplastic Carcinoma",
        "Thyroid Gland Squamous Cell Carcinoma",
        "Undifferentiated High Grade Pleomorphic Sarcoma of Bone",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Tumor Infiltrating Lymphocytes LN-145",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Tumor Infiltrating Lymphocytes LN-145-S1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-04-27",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-05-22T03:10:32.025Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03449108"
    },
    {
      "nct_id": "NCT02244463",
      "title": "A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Thyroid Cancer",
        "Differentiated Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "MLN0128",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2015-07",
      "completion_date": "2022-04-28",
      "has_results": true,
      "last_update_posted_date": "2024-01-12",
      "last_synced_at": "2026-05-22T03:10:32.025Z",
      "location_count": 3,
      "location_summary": "Newport Beach, California • Boston, Massachusetts • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02244463"
    },
    {
      "nct_id": "NCT03002623",
      "title": "CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Neoplasms",
        "Poorly Differentiated and Undifferentiated Thyroid Cancer",
        "Differentiated Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "CUDC-907",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 7,
      "start_date": "2016-12-22",
      "completion_date": "2018-02-12",
      "has_results": true,
      "last_update_posted_date": "2018-12-21",
      "last_synced_at": "2026-05-22T03:10:32.025Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03002623"
    },
    {
      "nct_id": "NCT04420754",
      "title": "Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Relapsed/Refractory Poorly Differentiated Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "AIC100 CAR T Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AffyImmune Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-09-28",
      "completion_date": "2030-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-05-22T03:10:32.025Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Chicago, Illinois • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04420754"
    }
  ]
}